📢 #ESMO26 is here; keep a look out for our conference update!
In this video, Dr @tnewsomdavis, who will be sharing an update on HER2-directed NSCLC, introduces the medical experts who will be joining us at ESMO
➡️Drs @LizzySmyth1 & @YJanjigianMD: #Gastric/GEJ cancer
➡️ Assoc. Prof. Gerald Prager: #CRC & #PanCan
➡️ Prof. Hong Jae Chon & Assoc. Prof. Lorenza Rimassa: #HCC / #LiverCancer
➡️ Dr Louise Lim: #NSCLC
➡️ Dr @jhaveri_komal: #BreastCancer
➡️ Dr @DrIacovelli: #ProstateCancer & #BladderCancer
What will new data mean for clinical practice?
🎬 Keep checking back to see the videos as soon as they’re released to find out: https://cor2ed.com/n-connect/programmes/highlights-from-esmo-2026/?media=0
Gastric/GEJ cancer update supported by an Independent Educational Grant from AstraZeneca. In Spain, the information displayed is exclusively directed to Healthcare Professionals empowered to prescribe or dispense medicinal products. Please do not distribute in media, supporting materials or communication channels aimed at the general public. HCC and HER2-directed NSCLC updates are supported by Independent Educational Grants from BeOne and Bayer, respectively. All other updates supported by COR2ED
All content is intended for HCPs only
#MedEd #OncTwitter #MedTwitter #pcsm #lcsm
394 浏览 · 8 赞 · 8 转发 · 0 回复
Early clinical antitumor activity of VRN101099 across diverse HER2-mutants in solid tumors
https://esmocongress.esmo.orgHealth-related quality of life from HER2CLIMB-05: A phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as 1L maintenance therapy for HER2+ mBC
https://esmocongress.esmo.orgSafety, social costs and quality of life (QOL) in HER2-positive (HER2+) breast cancer (BC) patients (pts) treated with pertuzumab + trastuzumab fixed-dose combination subcutaneous (PT FDC SC): The PERTURB study
https://esmocongress.esmo.orgA global, interventional, open-label trial of trastuzumab deruxtecan (T-DXd)–based therapy in first-line HER2-positive metastatic breast cancer: DESTINY-Breast Guide
https://esmocongress.esmo.orgEfficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.orgGene-expression profiling of HR+/HER2- breast cancers arising in germline BRCA1/2 mutation carriers
https://esmocongress.esmo.org来源：COR2ED · x.com